Multiple System Atrophy Pipeline is Expanding due to Major Pharma Companies, Pipeline Therapies and R&D Programmes

Multiple System Atrophy Pipeline

DelveInsight’s “Multiple System Atrophy (MSA) Pipeline Insights, 2021” research provides detailed insights into the market’s current clinical development status and growth prospects.

Some of the Key Highlights from the Multiple System Atrophy Pipeline Report

• Notable companies like Biohaven Pharmaceutical, Alterity Therapeutics, Stealth BioTherapeutics, AFFiRiS, others are testing their drug candidates for Multiple System Atrophy.

• Pipeline therapy for Multiple System Atrophy which is in Phase III of clinical trials include Verdiperstat while pipeline therapy such as ATH 434 is in Phase II clinical trials.

• SBT-272, pipeline therapy for Multiple System Atrophy is in the early stage of development i.e. Phase I.

• Some Multiple System Atrophy pipeline therapy such as PD04 is still in the preclinical stage of development.

Get more insights @ Multiple System Atrophy Pipeline Insights

Multiple System Atrophy: Disease Overview

Multiple System Atrophy (MSA) is a rare neurological illness characterised by autonomic dysfunction, tremors, sluggish movement, muscle rigidity, postural instability, and ataxia (often referred to as Parkinsonism). This is caused by progressive degeneration of neurons in several areas of the brain, including the basal ganglia, inferior olivary nucleus, and cerebellum.

Multiple System Atrophy: Symptoms

MSA’s initial symptoms are typically difficult to distinguish from those of Parkinson’s disease. It includes:

• Slowness of movement, tremor, or rigidity (stiffness)

• Clumsiness or incoordination

• Impaired speech, a croaky, quivering voice

• Fainting or lightheadedness due to orthostatic hypotension, a condition in which blood pressure drops when rising from a seated or lying down position

• Bladder control problems, such as a sudden urge to urinate or difficulty emptying the bladder.

Multiple System Atrophy: Treatment

MSA does not have a specific treatment. The goal of treatment is to keep the disease’s symptoms under control. Individuals with MSA may be prescribed drugs that are used to treat Parkinson’s disease, most commonly levodopa (administered in Sinemet tablets).

Get more information about the disease @ Multiple System Atrophy Symptoms, Causes and Diagnosis

Multiple System Atrophy Pipeline Analysis: Drug Profile

Verdiperstat: Biohaven Pharmaceutical

Biohaven is developing Verdiperstat as a potential first-in-class, oral, brain-penetrant, irreversible inhibitor of MPO as a therapy for MSA. Verdiperstat could possibly be used to treat a variety of additional diseases that are linked to oxidative stress, inflammation, and neurodegeneration.

Multiple System Atrophy Pipeline Therapies and Key Companies

• Verdiperstat – Biohaven Pharmaceutical

• ATH 434: Alterity Therapeutics

• SBT-272: Stealth BioTherapeutics

• PD04: AFFiRiS

Multiple System Atrophy Therapeutics Assessment

• By Product Type

• Monotherapy

• Combination Therapy

• By Stage

• Discovery

• Pre-Clinical

• Phase I

• Phase II

• Phase III

• Pre-registration

• By Route of Administration

• Inhalation

• Intravenous

• Oral

• Subcutaneous

• By Molecule Type

• Small Molecule

• Stem Cell Therapy

• Gene Therapy

• Targets

• Immune System

• Multiple Kinase

• Protease

• By Mechanism of Action

• Protease Inhibitors

• Immunomodulatory

• Multiple Kinase Inhibitors

Scope of the Report

Coverage: Global

MSA Key Players: Biohaven Pharmaceutical, Alterity Therapeutics, Stealth BioTherapeutics, AFFiRiS, among others

MSA Pipeline Therapies: Verdiperstat, ATH 434, SBT-272, PD04, and others

Table of Contents

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare and Biotech Blog Posts

Key questions answered in the Multiple System Atrophy Pipeline Report

• What are the options for treating Multiple System Atrophy?

• How many firms are working on remedies for Multiple System Atrophy?

• Which of these firms’ therapies are the most popular?

• What is the total number of Multiple System Atrophy therapies produced by each company?

• How many novel therapies are being developed for Multiple System Atrophy in the early, mid, and late stages?

• How many of the medications in development can be used on their own or in conjunction with other therapies?

• What are the most significant industry-industry and industry-academy cooperation, mergers and acquisitions, and licensure practises that will have an impact on Multiple System Atrophy?

Related Reports

Central Nervous System Lymphoma Pipeline Insights

Get comprehensive analysis of Central Nervous System Lymphoma pipeline therapies and key companies including Shandong New Time Pharmaceutical, AstraZeneca, Bristol-Myers Squibb, Janseen, Celgene, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/